While Wall Street obsesses over GLP-1 weight-loss drugs, Novo Nordisk's foundational diabetes business continues to deliver robust growth and exceptional returns on assets, presenting a durable investment thesis often overshadowed by the obesity narrative.
Facing the looming patent expiration of key drugs Revlimid and Eliquis, Bristol-Myers Squibb is making a strategic pivot, acquiring Orbital Therapeutics for $1.5 billion to pioneer in vivo RNA therapies. This high-stakes move aims to redefine the company's growth in oncology and autoimmune diseases.
AbbVie's $2.1 billion acquisition of Capstan Therapeutics signals a strategic pivot towards next-generation immunology treatments. The move aims to secure future revenue streams as the company navigates the post-Humira era, with analysts highlighting the transformative potential of its in vivo CAR-T platform.
Woodward (WWD) kicked off fiscal 2026 with robust earnings, driven by a surge in aerospace services and industrial sales. The company raised its full-year outlook but cautioned on supply chain pressures and announced a strategic wind-down of its volatile China On-Highway business.
Kforce reports stronger-than-expected Q4 2025 results, citing the highest sequential growth in its tech business since 2022. The company sees early signs of a market recovery, fueled by client demand for flexible talent to tackle AI-driven projects and foundational IT work.
Merck & Co. is laying the groundwork for its future in oncology beyond Keytruda, announcing a strategic investment in biotech Eikon Therapeutics and a major collaboration with diagnostic leader Guardant Health. The moves signal a targeted, partnership-driven strategy to bolster its pipeline and diagnostics capabilities in the competitive cancer therapy market.
In a landmark shift, Venezuela's interim government has enacted a sweeping reform of its oil industry, dismantling core socialist-era controls to attract foreign investment. While promising a production boost, the new hybrid system raises concerns about transparency, U.S. oversight, and whether it truly marks a clean break from the past.
Amid widespread anxiety over AI-driven job losses, a new report from the Yale Budget Lab finds little evidence of large-scale labor market disruption, raising questions about whether 'AI-washing' is being used to justify corporate layoffs.
Saks Global is closing most of its Saks OFF 5TH off-price stores across the U.S., leaving only a dozen locations open as it refocuses on core luxury and full-price retail after a recent Chapter 11 filing.
General Motors CEO Mary Barra attended a White House event where President Trump unveiled 'Project Vault,' a $12 billion initiative to create a strategic reserve of critical minerals aimed at securing U.S. industrial supply chains.
T-Mobile, the telecommunications giant headquartered in Washington, has filed official notice of permanent layoffs affecting nearly 400 employees across its Bellevue, Bothell, and Woodinville offices, citing evolving business needs.
The United States and India have reached a trade agreement that will significantly lower reciprocal tariffs and remove a contentious levy on Russian oil purchases, marking a potential thaw in economic relations.
An independent financial analysis of Duke University has found the institution possesses substantial reserves and strong cash flow, raising faculty criticism over recent staff reductions and budget cuts framed as necessary austerity measures.
Disney's first-quarter earnings call highlighted a landmark $10 billion in Parks revenue and strong film performance, while the looming CEO succession question lingered in the background.
Canopy Growth's shares have plummeted over 99% in five years, yet analysts warn its challenges run deeper than its stock price suggests. Despite recent U.S. regulatory changes, structural industry headwinds and the company's own track record make it a speculative play at best.
Newly filed state documents reveal the geographic breakdown of Amazon's latest workforce reduction in Washington, with T-Mobile and International Paper also submitting layoff notices affecting hundreds more employees across the state.
The severe winter storm Fern, leaving nearly a million customers without power, has starkly highlighted the U.S. electrical grid's persistent vulnerabilities. This comes despite repeated warnings from reliability monitors about the system's growing strain.
Clinical-stage biotech Erasca (ERAS) has seen its stock skyrocket over the past 12 months, hitting a multi-year high. While technical momentum is strong, the company remains pre-revenue, with its fate tied to future drug approvals, presenting a classic high-risk, high-reward scenario for investors.
Shares of Napco Security Technologies surged more than 10% after the company posted quarterly results that handily exceeded analyst forecasts, driven by robust revenue growth and significant margin expansion.
New clinical imaging data for Molecular Partners' experimental radiotherapeutic MP0712, targeting the DLL3 protein in cancers like small cell lung cancer, show favorable tumor targeting and healthy organ clearance. The company confirms its U.S. Phase I/II trial is now open for patient screening.
